Director shareholdings

Apr 24, 2009

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

HomeRNS NewsDirector ShareholdingDirector shareholdings
RNS Number : 0872R
Advanced Medical Solutions Grp PLC
24 April 2009
 



For Immediate release

24 April 2009

Advanced Medical Solutions Group PLC 

(“AMS” or the “Company”)

Directors’ shareholdings

Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, announces that the following Directors purchased ordinary shares of 5 pence each (“Ordinary Shares”) on 23 April 2009, as part of the Deferred Share Bonus Plan. These Ordinary Shares were bought at a price of 34 pence per share and, under the terms of the Plan, will be held in trust on their behalf.

Director

Shares purchased

Resultant holding

% of issued share capital

Don Evans, Chief Executive Officer

55,882

849,591

0.59

Mary Tavener, Finance Director

37,352

221,130

0.15

Chris Meredith, Commercial Director

37,352

111,890

0.08

In addition, the Board granted new share options to the Directors under the Advanced Medical Solutions Long Term Incentive Plan (the ‘LTIP’) on 23 April 2009. These options are subject to certain performance criteria over a three year period to vest.

Director

LTIPs granted

Resultant holding

Don Evans

293,843

3,295,016

Mary Tavener

193,408

2,407,979

Chris Meredith

589,234

1,797,234

For further information, please contact:

Advanced Medical Solutions Group plc
Don Evans, Chief Executive Officer

Mary Tavener, Finance Director
www.admedsol.com

Tel: +44 (0) 16 0654 5508

Buchanan Communications

Mark Court 

Stasa Filiplic

Tel: +44 (0) 20 7466 5000

Investec Bank plc

Richard Jones

Tim Pratelli

Tel: +44 (0) 20 7597 5970 

Notes to Editors:

Advanced Medical Solutions is a leading company in the development and manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure.  

The advanced woundcare products are based on the moist wound healing principle. AMS uses its inhouse technology to provide a vertically integrated ‘one stop shop’ for all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.

The acquisition of a 49.4% stake in Corpura BV in May 2008 strengthened AMS’s position in hydrophilic polyurethane foam – the largest and fastest growing segment of the advanced woundcare market.

AMS’ technology in cyanoacrylate based tissue adhesives is used for the closure of small cuts and trauma wounds through to large surgical incisions, and also for protecting or sealing skin to prevent breakdown or infection. 

AMS’ products which currently serve the majority of the key global markets are sold either direct or through strategic partners and distributors. 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

RDSCKNKPABKDBQB

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.